Current vaccination strategies for prostate cancer
Joniau, Steven × Abrahamsson, Per-Anders Bellmunt, Joaquim Figdor, Carl Hamdy, Freddie Verhagen, Paul Vogelzang, Nicholas J Wirth, Manfred Van Poppel, Hendrik Osanto, Susanne #
European Urology vol:61 issue:2 pages:290-306
The first therapeutic cancer vaccine demonstrating effectiveness in a phase 3 study was approved by the US Food and Drug Administration on 29 April 2010. The pivotal trial demonstrated overall survival (OS) benefit in patients treated with antigen-loaded leukapheresis cells compared with a control infusion. Results of other prostate cancer (PCa) vaccination strategies are awaited, as this approach may herald a new era in the care for patients with advanced PCa.